Ida Normiha Hilmi

机构：University of Malaya · ORCID：0000-0001-7091-0032

发表论文 161 篇 · 总被引 5811 次 · h-index 37

代表论文

• Global evolution of inflammatory bowel disease across epidemiologic stages (2025 · Nature · 被引 438)
• Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies (2024 · The Lancet · 被引 103)
• Primary caregiver burden and undiagnosed mental health illness in out-patients with inflammatory bowel disease—A multicentric prospective survey from the IBD Emerging Nations’ Consortium (2024 · Indian Journal of Gastroenterology · 被引 10)
• Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial (2026 · ˜The œLancet. Gastroenterology & hepatology · 被引 8)
• IBD in transition: a decade of data from the Malaysian Kinta Valley cohort (2026 · Inflammatory Bowel Diseases · 被引 6)
• Ten missteps in the management of inflammatory bowel disease in Asia: An expert report by the Asian Pacific Association of Gastroenterology Working Group on Inflammatory Bowel Disease (2024 · Journal of Gastroenterology and Hepatology · 被引 6)